Inhibition of calmodulin and protein kinase C by amiodarone and other class III antiarrhythmic agents

Cardiovascular Drugs and Therapy
P J SilverA M Ezrin

Abstract

Class III antiarrhythmic agents may prolong refractoriness via modulation of ion channels, which may be sensitive to Ca2+ regulatory proteins or enzymes. Accordingly, the purpose of this study was to quantitate the effects of several structurally diverse class III antiarrhythmic agents on calmodulin-regulated enzymes and protein kinase C activity, and to evaluate the ability of these agents and known calmodulin antagonists to prolong cardiac refractoriness in vivo. The rank order of potency (IC50;microM) of selected class III antiarrhythmic agents and reference calmodulin antagonists as inhibitors of calmodulin-regulated phosphodiesterase activity were: calmidazolium (0.12 microM) greater than amiodarone (0.62 microM) greater than desethylamiodarone (1.5 microM) greater than trifluoperazine (4.3 microM), bepridil (5 microM) greater than W-7 (7.5 microM), clofilium (13 microM). Similar concentration-related inhibition was evident in a second calmodulin-regulated system, inhibition of myosin light-chain phosphorylation and superprecipitation of arterial actomyosin. Sotalol and tetraethylammonium were inactive at 100 microM. Protein kinase C activity was also inhibited by some of these agents; desethylamiodarone (IC50 = 11 microM)...Continue Reading

References

Apr 1, 1979·The Journal of Physiology·D DiFrancesco, P A McNaughton
Jan 1, 1985·The Journal of Membrane Biology·I B Levitan
Jan 1, 1974·Methods in Enzymology·J D Corbin, E M Reimann
Apr 1, 1984·Journal of Clinical Pharmacology·E M Vaughan Williams
Jul 16, 1984·European Journal of Biochemistry·M Zimmer, F Hofmann
Oct 1, 1983·American Heart Journal·D W HoltG C Storey

❮ Previous
Next ❯

Citations

Aug 21, 1992·Pharmaceutisch Weekblad. Scientific Edition·R Mannhold, H Timmerman
Sep 25, 2009·Naunyn-Schmiedeberg's Archives of Pharmacology·Jakob GiertenDierk Thomas
Dec 21, 2002·Nihon yakurigaku zasshi. Folia pharmacologica Japonica·Toru Maruyama, Hiroyuki Ito
Nov 26, 1993·The American Journal of Cardiology·L Ceremuzyński
Feb 23, 2018·Neuro-ophthalmology·Katrin FaslerKlara Landau

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anti-Arrhythmic Drug Therapies

Anti-arrhythmic drugs are used to prevent abnormal heart rhythms. These medications are used in conditions including, ventricular tachycardia, ventricular fibrillation and atrial fibrillation. Discover the latest research on anti-arrhythmic drug therapies here.

Antiarrhythmic Agents: Mechanisms of Action

Understanding the mechanism of action of antiarrhythmic agents is essential in developing new medications as treatment of cardiac arrhythmias is currently limited by the reduced availability of safe and effective drugs. Discover the latest research on Antiarrhythmic Agents: Mechanism of Action here.